UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): **September 25, 2017**

ADVAXIS, INC.
(Exact Name of Registrant as Specified in Charter)

Delaware	**001-36138**	**02-0563870**
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

305 College Road East
Princeton, New Jersey, 08540
(Address of Principal Executive Offices)

(609) 452-9813
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act.

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act.

[ ] Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company [ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act [ ]

Item 8.01. Other Events.

Attached hereto as Exhibit 99.1 and incorporated herein by reference is a PowerPoint presentation, including a corporate overview of Advaxis, Inc., which will be made available on its website at www.advaxis.com.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

The following exhibit is filed as part of this report:

Exhibit Number	Description
99.1	Company PowerPoint presentation.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Advaxis, Inc.
(Registrant)

Date: September 25, 2017

By: */s/ Sara Bonstein*
Sara Bonstein
Executive Vice President and
Chief Financial Officer

INDEX TO EXHIBITS

Exhibit Number	Description
99.1	Company PowerPoint presentation.

Forward-Looking Statements

This presentation contains forward-looking statements, including, but not limited to, statements regarding Advaxis' ability to develop and commercialize the next generation of cancer immunotherapies, and the safety and efficacy of Advaxis' proprietary immunotherapies. These forward-looking statements are subject to a number of risks including the risk factors set forth from time to time in Advaxis' SEC filings including, but not limited to, its report on Form 10-K for the fiscal year ended October 31, 2016, which is available at http://www.sec.gov.

Any forward-looking statements set forth in this presentation speak only as of the date of this presentation. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof other than as required by law.

ADVAXIS

IMMUNOTHERAPIES™

A late-stage biotechnology company creating cancer immunotherapies that enlist the body's own immune system to fight cancer.

Advaxis' proprietary *Lm* targeted immunotherapy is a new approach toward an effective cancer vaccine.

Our *Lm* Technology has achieved safety and efficacy endpoints in early-stage trials and is the platform for our continued focus on the science, discovery, development and commercialization of cutting-edge cancer treatments.

Advaxis, Inc: Investment Snapshot

ADVAXIS IMMUNOTHERAPIES™

Flexible platform technology	• Platform based on attenuated *Lm* (*Listeria Monocytogenes)* • Multiple approaches to impacting the immune system • Manageable safety profile: common AEs are mostly mild to moderate and resolve within 48 hours
Broad pipeline with four franchises	• 3 clinical stage programs: HPV-Associated Cancers, Prostate Cancer and ADXS-NEO individualized targeting in partnership with Amgen Inc. • Novel preclinical program: ADXS-HOT with multiple products targeting multiple cancers
Lead program in Phase 3	• HPV-targeting program includes axalimogene filolisbac and ADXS-DUAL • Ongoing registrational study of axalimogene filolisbac in high risk locally advanced cervical cancer • Registrational study of ADXS-DUAL in metastatic cervical cancer in combination with Opdivo® to start in 1H 2018
Ability to combine with other I-O agents	• Demonstrated preclinical synergy with multiple checkpoint inhibitors and co-stimulatory agents • Three clinical trials in combination with PD-1/PDL-1 inhibitors
Strong partnerships	• 3 clinical collaborations evaluating combination therapies (Merck, AstraZeneca, Bristol-Myers Squibb) • Global collaboration for ADXS-NEO with Amgen on novel program targeting neoepitopes
Experienced management team	• Deep and broad experience in pharmaceutical drug development and commercialization

Who is Advaxis?

Company Overview

Who is Advaxis?

Creating Next-Generation Cancer Immunotherapies, Using a Proprietary *Lm* Platform

ADVAXIS IMMUNOTHERAPIES™

Company Overview



Multiple inflection points beginning in 2018

Product Franchise Overviews

HPV-associated cancers	Cervical (CC), head & neck, anal **Products:** axalimogene filolisbac (AXAL) (Phase 3 for CC), ADXS-DUAL (Entering Phase 3 for CC)
Personal Neoantigen Program	Multiple cancers **Products:** ADXS-NEO (Entering Phase 1)
Shared Neoantigens (Hotspot Mutations)	Multiple cancers, Multiple products **Products:** ADXS-HOT Constructs (Pre-IND)
Prostate Cancer	**Products:** ADXS-PSA (Phase 2), Preclinical Product Candidates

Note: * As of July 31st 2017.

Who is Advaxis?
Experience and Expertise are Our Greatest Assets

ADVAXIS IMMUNOTHERAPIES™

Anthony Lombardo
Interim Chief Executive Officer

GE Healthcare · Philips · Bracco · ALI Technologies · EZEM

Robert Petit
Chief Scientific Officer

Bristol-Myers Squibb Company · Pharmacia · MGI Pharma · Aesgen

Sara Bonstein
Chief Financial Officer

ImClone Systems Incorporated · Lilly · Johnson & Johnson

Chris Duke
Chief Operating Officer

NPS Pharma · Amicus Therapeutics



Michael Grace
VP, Technical Operations

NPS Pharma · Bristol-Myers Squibb Company

Thomas Hare
Sr. VP, Product Development

Pharmaceutical Sciences · Incyte · Bristol-Myers Squibb Company

Robert Ashworth
Sr. VP, Regulatory, Quality & Compliance

NPS Pharma · Otsuka · Forest Laboratories, Inc.

Ranya Dajani
VP, Corporate Development

Bristol-Myers Squibb Company

ADVAXIS
IMMUNOTHERAPIES™



Our Differentiator:

Lm Technology™ Platform

Harnessing the Immune System with *Lm* Technology™
A Demonstrated, Personalized Next-Generation Cancer Immunotherapy Platform

ADVAXIS IMMUNOTHERAPIES™

How it works: Live, attenuated strain of Listeria monocytogenes (*Lm*) is infused into the patient where they are taken up by dendritic cells, stimulate a potent immune activation, generate new cancer targeting immune cells, and reduce the tumor's protective shield, enabling tumor destruction.



Unique Benefits:

Full immune system activation	Manageable safety profile	Enhanced potency with compound MOA	Synergies with checkpoint inhibitors
Activation of both the innate and adaptive T cell mediated responses, as antigens present on both MHC Class I & II generating broad anti-cancer immunity	Attenuated listeria is unable to travel between cells; Flu-like symptoms have been transient and associated with infusion; no long-term toxicity seen to date	Enhanced potency of the immune response due to the fusion of HPV antigen to tLLO; Multiple repeat treatments not impaired by neutralizing antibodies	Potential for combination synergies; Trials with PD-1, PD-L1, CTLA4 inhibitors and costimulatory agonists

Harnessing the Immune System with *Lm* Technology™
A Demonstrated, Personalized Next-Generation Cancer Immunotherapy Platform

ADVAXIS IMMUNOTHERAPIES™

The Power of *Lm*

- **Proprietary technology**: protected by a range of patents, stretching into 2037
- **Clinically validated**: unprecedented improvement of 12 month survival rates in Ph 2 metastatic cervical cancer studies, warranting confirmatory study
- Safety profile **generally well-tolerated** across 370 patients in multiple trials
- Flexible platform: targets **multiple cancers in multiple ways**, constantly evolving
- Strong clinical development program: built on partnerships with industry leaders, including **Amgen, AstraZeneca, BMS, Merck**

The Potential of *Lm*

- **Target and treat new cancers** as additional antigens are identified and introduced into the platform
- **Combine with checkpoint inhibitors** (nivolumab, pembrolizumab and durvalumab) to improve outcomes
- Create **breakthrough in individualized immunotherapy** with ADXS-NEO
- Target shared hotspot mutations to treat common cancers with **"off-the shelf" ADXS-HOT**

Lm Technology Platform: Unmet Needs in Immuno-Oncology

ADVAXIS IMMUNOTHERAPIES™

Today's Immunotherapy Landscape

Checkpoint Inhibitors/Co-stimulatory Agonists: Impressive Successes in Recent Years
- Combo therapy likely required for optimal treatment
- Not all patients respond
- Many who respond will later progress
- Not effective in all tumor types

CAR-T: May evoke responses in patients when other treatments stop working
- Limited to liquid tumors
- Meaningful toxicity concerns
- Costly; potential treatment delays

Cancer Vaccines: Activates immune system to destroy tumor
- Historically unsuccessful
- Combo therapy likely required for optimal treatment
- Neutralizing antibodies develop, preventing further treatments

Lm Technology Complements the Landscape and Addresses Unmet Needs

Immune System Activation: Potent T cell responses to multiple cancer specific targets simultaneously

Safety Profile: Generally well tolerated, with mild to moderate, transient adverse events

Combinations optimize checkpoint performance

Immediately available for treatment with low cost of goods

ADVAXIS
IMMUNOTHERAPIES™

Opportunity, Accomplishments & Company Direction

The Future of *Lm* Technology™ Next-Generation Cancer Immunotherapies

Demonstrated Achievements in CC, Poised for Expansion to Major Cancers

ADVAXIS IMMUNOTHERAPIES™

Significant clinical and regulatory milestones are Proof of Concept…

2013

Regulatory:

FDA Orphan Designation: Anal, Head & Neck Cancers

2014

Clinical:

Ph 2 in India: 34.9% 12-month OS

Regulatory:

FDA Orphan designation Invasive CC

EMA Orphan designation: Anal

2016

Regulatory:

FDA Fast Track: HRLA CC

HRLA AC

EMA ATMP: HRLA CC

2017

Clinical:

GOG-0265: 38.5% 12-month OS in CC

BrUOG Study: 90% relapse-free survival in AC

FAWCETT: 28% disease control rate in AC

Regulatory:

EMA ATMP for manufacturing quality and non-clinical data

2018+

Regulatory:

EMA Marketing authorization application approval decision expected: Metastatic / recurrent cervical (2H)

Active partnering discussions underway

… Advaxis will continue to expand the utility of *Lm* Technology, **expanding beyond HPV related cancers into major cancers** to enhance the lives of more patients worldwide while maximizing shareholder value.

CC=cervical cancer; HRLA=high risk, locally advanced; ATMP=advanced therapeutics medicinal product; OS=overall survival; GOG= Gynecological Oncology Group; BrUOG=Brown University Oncology Research Group; AC=anal cancer

Lm Technology's Three Unique Attributes: An Ideal Vector For Immunotherapy

ADVAXIS IMMUNOTHERAPIES™

***Lm* Technology's comprehensive immune stimulation and priming redirects a "pathogen" response against the cancer**



Lm Technology Vector



Expansion of *Lm* Technology Beyond HPV:
Advaxis Focus on Four Key Franchises

ADVAXIS IMMUNOTHERAPIES™

HPV-Related Cancers
The Proof of Concept

NEO
Individualized Neoantigens

HOT
Expansion into the Most Common Cancer Types

Prostate Cancer

Expansion of *Lm* Technology Beyond HPV:
Advaxis Focus on Four Key Franchises

ADVAXIS IMMUNOTHERAPIES™

HPV-Related Cancers

- Demonstrated safety and efficacy of axalimogene filolisbac (AXAL) – **highest 12 mo. OS** in metastatic CC as observed by GOG across many trials in that population
- ADXS-DUAL **increases viral coverage** of AXAL
- Path to CC commercialization:
  - **Two registrational trials** ongoing in 2018, one in combo w/ nivolumab
  - **EU Conditional application** submission Dec 2017
- Opportunistic funding approaches for Head and Neck, Anal

Hotspot Mutation Therapy Program

- Proprietary program will apply the clinical potential of *Lm* Technology to a broad array of common cancer types
- Constructs will target shared, tumor-specific hotspot mutations
- IND filing planned for the first constructs in 2018

Individualized Neoantigen Therapy

- Partnership with Amgen Inc.
- Potential to be a major step forward in individualized medicine in cancer, driving innovation and significant commercial opportunities
- IND approved; with first patient dose planned for 1H 2018

Prostate Cancer

- Significant opportunity; high unmet medical need and sizeable patient population
- Phase 1/2 trial with Merck's pembrolizumab ongoing
  - Monotherapy activity promising
  - Combination data in 2018

The Future of Lm Technology™
Clinical Trial Programs – In Progress and On the Horizon

ADVAXIS IMMUNOTHERAPIES™



Business Acceleration
Multiple inflection points beginning in 2018

ADVAXIS IMMUNOTHERAPIES™

PROGRAM	MILESTONE	TARGET
ADXS-PSA	Metastatic Prostate Ph1/2 Combination with pembrolizumab Part A Monotherapy	*Completed*
Axalimogene filolisbac	Recurrent / Metastatic Cervical Cancer EU Conditional Approval Filing	Q4 2017
ADXS-DUAL	Metastatic Cervical Ph 3 Combination with nivolumab IND Filing	2H 2017
ADXS-DUAL	Metastatic Cervical Ph 3 Combination with nivolumab Trial Initiation	1H 2018
ADXS-NEO	Ph 1 Initiation	1H 2018
ADXS-PSA	Metastatic Prostate Ph1/2 Combination with pembrolizumab Part B Monotherapy Combination Therapy Data	2018
ADXS-DUAL	Announce planned IST in Head and Neck	2018
ADXS-HOT	Multiple INDs Filed First in Human – 1 Tumor Type	2018
Axalimogene filolisbac	Metastatic Cervical Ph 1/2 Combo with durvalumab Part 1 Combination Therapy: Dose Escalation, Dose Determination	*Completed*
	Part B Expansion Interim Readout	2019

EU= European Union; IND= Investigational New Drug; IST= Investigator Initiated Trial

ADVAXIS
IMMUNOTHERAPIES™

Proof of Concept: HPV-Associated Cancers

Expanding *Lm* Technology™ into the Cervical Cancer Market

The Opportunity for Our HPV Franchise

39,800
new U.S. cancer cases per year where HPV is found in the body; HPV causes 31,500 of these cancers[2]

4,210
deaths from cervical cancer expected in the U.S. in 2017[1]

58,373
European women diagnosed with cervical cancer per year[4]

24,404
estimated deaths from cervical cancer per year in Europe[4]

2nd most common
female cancer for those aged 15 to 44 in Europe[4]

12,820
new invasive cervical cancer cases estimated in the U.S. in 2017[1]

3 months
Average extension of life provided by current treatments for metastatic cervical cancer

Vaccination rates
vary widely from state to state[3]

5-year survival rates
very poor in late stage cancer[1]

2nd most frequent
cause of cancer-related death worldwide, accounting for nearly 300,000 deaths annually[3]

Persistent/ recurrent metastatic cervical cancer is fatal, with no FDA approved treatment available.

1. American Cancer Society. 2. Centers for Disease Control and Prevention 3. National Institutes of Health. Fact Sheets: Cervical Cancer. October 2010. 4. HPV Information Centre.

Cervical Cancer and Axalimogene Filolisbac: Proof of Concept for *Lm* Technology

ADVAXIS IMMUNOTHERAPIES™

Phase 2 Study in India: Prolonged Survival and Tumor Response in Randomized, Multicenter Phase 2 Study in Recurrent/ Refractory CC Illustrated the Promise of *Lm* Technology[1]

- ✓ 34.9% 12-month survival rate (38/109), 3 durable CRs observed

GOG-0265: Unprecedented improvement of survival rates in Recurrent / Metastatic Cervical Cancer Confirmed the Findings[2]

- ✓ 38.0% 12-month survival rate (19/50); highest achieved to-date in GOG PRmCC studies to date, 1 durable CR observed
  - ✓ GOG Model-Predicted 12 month survival was 24.5%, based on the characteristics of patients in 0265
- ✓ Primary efficacy and safety endpoints met



Source: GOG-0265 Clinical Study



Stage One of GOG-0265

This strong body of clinical evidence of safety and efficacy led to decision to file for conditional approval in the EU by end of 2017.
Active partnering discussions underway

Safety

PRmCC=Persistent Recurrent Metastatic Cervical Cancer; GOG= Gynecological Oncology Group; CR= complete response
1. Data Presented at ASCO 2014. 2. Data presented at SGO 2017.

HPV-Related Cancers: Regulatory Pathway

ADVAXIS IMMUNOTHERAPIES™

ADVANCE Metastatic Combination Study with ADXS-DUAL and nivolumab

- Metastatic cervical cancer is an area of high unmet need
- Combination of ADXS-DUAL with nivolumab: significant opportunity to improve patient outcomes vs. standard of care
- ADXS-DUAL provides enhanced targeting of HPV-18
- Opportunity for interim analysis
- Planned start: 1H 2018

Bristol-Myers Squibb

ADXS-DUAL

AIM2CERV Adjuvant Therapy with axalimogene filolisbac

- High unmet medical with no approved treatments available
- Currently enrolling in 8 countries
- Data expected 2020/ 2021
- Confirmatory study to support EU conditional approval (filing December 2017)

Study Design

Our cervical drug candidates remain the cornerstone of our *Lm* Platform.

ADVAXIS
IMMUNOTHERAPIES™

Individualized Neoantigens

Capitalizing on the Individualized Medicine Market with *Lm* Technology™
The Opportunity for ADXS-NEO

ADVAXIS IMMUNOTHERAPIES™



Our *Lm* Technology is ideal for applications in individualized medicine, a growing market

Bringing ADXS-NEO to Patients

Massive Parallel Sequencing of tumor biopsies

Identify neoepitopes

Patient-specific Immunotherapies

Advaxis designs vector based on neoepitopes and bioengineers *Lm*

Patient's Hospital or Treating Institution

Treat patient with personalized immunotherapy vector programmed to his/her neoepitopes

ADXS-NEO in Action

ADVAXIS IMMUNOTHERAPIES™

1. Once injected into the patient, *Lm* Technology taken up by antigen-presenting cells
2. The bacteria secrete tumor-associated antigens into the liquid interior of the APC
3. The antigens are then processed and presented to T cells
4. Goal: help T cells recognize a wide range of tumor-associated antigens and attack cancer cells with the same antigens



Capitalizing on the Individualized Medicine Market with *Lm* Technology™
ADXS-NEO Study Design

A Phase 1 Dose-Escalation Study of Advaxis (ADXS) NEO Expressing Personalized Tumor Antigens

Tumor Types:
Metastatic Microsatellite Stable Colon Cancer
Metastatic Squamous Histology Head and Neck Cancer
Metastatic Non-Small Cell Lung Cancer

Dose escalation phase
N= 9 - 18
3 + 3 design
1 x10^9, 2 x10^9, or 4 x10^9 CFU
Q3 Weekly

Expansion Phase
N=30 (10 per tumor type)
Up to 1 year dosing

Endpoints

Primary:
Tolerability/Safety

Secondary:
Clinical activity
RP2D

Exploratory:
Immunological

In partnership with AMGEN

CFU= Colony-Forming Unit; RP2D= Recommended Phase 2 Dose

ADVAXIS
IMMUNOTHERAPIES™

Further Expansion into Common Cancer Types: ADXS-HOT

Leveraging *Lm* Technology™ to Treat Most Common Cancers
Introducing the ADXS-HOT Franchise

ADVAXIS IMMUNOTHERAPIES™

ADXS-HOT immunotherapies combine multiple hotspot mutations (neoantigens), designed to increase potential for immunogenicity



- Targets: Common (public or shared) "Hot Spot" mutations in tumor driven genes, designed to increase potential for immunogenicity
- A multi-product program, with each product addressing one of the most common types of cancer
- Can be used as monotherapy and/or in combination with other cancer treatments like checkpoint inhibitors, radiation therapy, or other neoepitope treatments
- Constructs "Off the shelf" and available for patients to start treatment immediately
- Constructs can be manufactured in bulk with good stability keeping cost of goods low vs. "individualized" products
- INDs for first constructs expected in 2018

Benefits of Lm Technology in Hotspot Targeting

The capacity of the Lm-LLO vector allows coverage of nearly all of the mutations that may occur in one single targeted product.



Leveraging *Lm* Technology™ to Treat Most Common Cancers
The Opportunity for ADXS-HOT

ADVAXIS IMMUNOTHERAPIES™

What is a "Hotspot" mutation?[1,2]

- Growth of "Hotspot" mutations (i.e. somatic mutations) is one of the major mechanisms responsible for oncogenesis
- Genetic profiling of tumors has produced valuable insights into the "Hotspots" that define individual cancer types
- Many hotspot mutations are seen in multiple patients with cancer. These are referred to as "shared" or "public" neoantigens

The ADXS-HOT Program will generate several "off-the-shelf" products that target multiple shared hotspot neoantigens using the latest innovations in *Lm* Technology™

Cancers Ranked by "Hotspot" mutations[3]



1. Garraway, L.A. & Lander, E.S. Lessons from the cancer genome. *Cell* 153, 17–37 (2013). 2. Vogelstein, B. et al. Cancer genome landscapes. *Science* 339, 1546–1558 (2013).
3. Chang et al. Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. *Nature Biotechnology* 34, 155–163 (2016)


ADVAXIS
IMMUNOTHERAPIES™
Expansion into Prostate Cancer

Expanding *Lm* Technology™ into the Prostate Cancer Market

The Opportunity in Prostate Cancer

161,360
of new prostate cancer cases estimated in the U.S. in 2017[1]

1 in 36
men will die from prostate cancer[2]

9.6%
of all new cancer cases in the U.S. are prostate cancer[1]

1 in 7
men will be diagnosed with prostate cancer during his lifetime[2]

26,730
deaths from prostate cancer expected in U.S. in 2017[1]

To date, checkpoint inhibitor monotherapy has not shown significant activity in prostate cancer.[3] Combining ADXS-PSA with Keytruda® could optimize performance and improve outcomes.

1. NIH 2017 SEER Statistics. 2. American Cancer Society. 3. Goswami S. et al. Immune Checkpoint Therapies in Prostate Cancer. *Cancer J.* 2016 Mar-Apr; 22(2): 117–120.

ADXS-PSA Metastatic Prostate Cancer
Phase 1/2 Combination with KEYTRUDA® (pembrolizumab) - (KEYNOTE-046)

ADVAXIS IMMUNOTHERAPIES™

Inclusion Criteria:

- Progressive metastatic CRPC
- ≤2 prior systemic treatment regimens or ≤1 prior chemotherapeutic in the metastatic setting

MERCK

Part B Expansion: Endpoints
- Safety
- Efficacy
- Immunologic Activity



https://clinicaltrials.gov/ct2/show/NCT02325557 RP2D= Recommended Phase 2 Dose

ADXS-PSA Metastatic Prostate Cancer
Phase 1/2 Combination with KEYTRUDA® (pembrolizumab) - (KEYNOTE-046)

ADVAXIS IMMUNOTHERAPIES™

Inclusion Criteria:

- Progressive metastatic CRPC
- ≤2 prior systemic treatment regimens or ≤1 prior chemotherapeutic in the metastatic setting

MERCK

Part B Expansion: Endpoints
- Safety
- Efficacy
- Immunologic Activity



Current Status:
- Part A completed and presented at CRI-CIMT-EATI-AACR 2017 and SITC 2017
- Part B combination RP2D dose determination completed
- Part B expansion enrolling – preliminary clinical data in 2018

https://clinicaltrials.gov/ct2/show/NCT02325557 RP2D= Recommended Phase 2 Dose


ADVAXIS
IMMUNOTHERAPIES™
Upcoming Milestones

Business Acceleration
Multiple inflection points beginning in 2018

ADVAXIS IMMUNOTHERAPIES™

PROGRAM	MILESTONE	TARGET
ADXS-PSA	Metastatic Prostate Ph1/2 Combination with pembrolizumab Part A Monotherapy	*Completed*
Axalimogene filolisbac	Recurrent / Metastatic Cervical Cancer EU Conditional Approval Filing	Q4 2017
ADXS-DUAL	Metastatic Cervical Ph 3 Combination with nivolumab IND Filing	2H 2017
ADXS-DUAL	Metastatic Cervical Ph 3 Combination with nivolumab Trial Initiation	1H 2018
ADXS-NEO	Ph 1 Initiation	1H 2018
ADXS-PSA	Metastatic Prostate Ph1/2 Combination with pembrolizumab Part B Monotherapy Combination Therapy Data	2018
ADXS-DUAL	Announce planned IST in Head and Neck	2018
ADXS-HOT	Multiple INDs Filed First in Human – 1 Tumor Type	2018
Axalimogene filolisbac	Metastatic Cervical Ph 1/2 Combo with durvalumab Part 1 Combination Therapy: Dose Escalation, Dose Determination	*Completed*
	Part B Expansion Interim Readout	2019

EU= European Union; IND= Investigational New Drug; IST= Investigator Initiated Trial

Advaxis, Inc: Investment Snapshot

ADVAXIS IMMUNOTHERAPIES™

Flexible platform technology	• Platform based on attenuated *Lm* (*Listeria Monocytogenes)* • Multiple approaches to impacting the immune system • Manageable safety profile: common AEs are mostly mild to moderate and resolve within 48 hours
Broad pipeline with four franchises	• 3 clinical stage programs: HPV-Associated Cancers, Prostate Cancer and ADXS-NEO individualized targeting in partnership with Amgen Inc. • Novel preclinical program: ADXS-HOT with multiple products targeting multiple cancers
Lead program in Phase 3	• HPV-targeting program includes axalimogene filolisbac and ADXS-DUAL • Ongoing registrational study of axalimogene filolisbac in high risk locally advanced cervical cancer • Registrational study of ADXS-DUAL in metastatic cervical cancer in combination with Opdivo® to start in 1H 2018
Ability to combine with other I-O agents	• Demonstrated preclinical synergy with multiple checkpoint inhibitors and co-stimulatory agents • Three clinical trials in combination with PD-1/PDL-1 inhibitors
Strong partnerships	• 3 clinical collaborations evaluating combination therapies (Merck, AstraZeneca, Bristol-Myers Squibb) • Global collaboration for ADXS-NEO with Amgen on novel program targeting neoepitopes
Experienced management team	• Deep and broad experience in pharmaceutical drug development and commercialization